Companies · Pharmaceuticals

Havix Group, Inc

HOSCHTON · Pharmaceuticals

Diligence memoA one-page analyst read on Havix Group, Inc — recommendation, valuation, rhythm, risks.
$3.0M
Total raised · real
3
Rounds
1.2×
Latest step-up
Top 68%
Sector rank · raised
Seed
Latest stage · inferred · Fri Oct 20 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Havix Group, Inc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.38× the median modeled value of Seed Pharmaceuticals companies in 2016–2018 (71 peers) — value vs value, same stage and era.
Dormant
  • Last raise 8.7 yr ago; this sector typically re-raises about every 13 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Havix Group, Inc is one of 1613 Pharmaceuticals companies tracked from HOSCHTON. By capital raised it ranks in the long tail (ahead of 33% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
1
Investors (latest)
2015
Year incorporated
2017-10-20
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$25M$50M$75M$100MSeed · 2015-08-10 Raised $1.9M (real) Modeled valuation $71M (est)$1.9M$71MSeed2015Seed · 2017-02-01 Raised $500K (real) Modeled valuation $19M (est)$500K$19MSeed2017Seed · 2017-10-20 Raised $600K (real) Modeled valuation $23M (est)$600K$23MSeed2017+$500K+$600KCumulative $3.0M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.9M · 2015
Seed extension$500K · 2017
Seed extension$600K · 2017

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$22.8M
Base estimate est.
$454K
Conservative case
$179.1M
Upside case
$3.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $71.3M · 2015-08-102015Seed · modeled $19.0M · 2017-02-01Seed · modeled $22.8M · 2017-10-202017
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
6.0 yr
Elapsed time used
8.7 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$1.4M/yr
Capital velocity
10.9 yr
On record since
2015
First round
3
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.4× of median
This company$3.0M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.4× of median
This company$600K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.3× of median
This company$22.8M
Sector median$76.1M

Raised more than 33% of sector peers (real $). Modeled value above 29% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #61 of 71.

This companyCohort peer
$10.0M$100.0M$1.0B$1.0M$10.0MCapital raised (log)Chase Therapeutics Corp · Seed Raised $5.3M · modeled $152.2M (est)Acura Pharmaceuticals, Inc · Seed Raised $4.0M · modeled $152.2M (est)Paragon Biosciences Skyline Capital, LLC · Seed Raised $4.0M · modeled $150.9M (est)Phoenix PharmaLabs Inc · Seed Raised $3.5M · modeled $133.1M (est)Saghmos Therapeutics, Inc. · Seed Raised $3.5M · modeled $133.1M (est)Immucell Corp /De/ · Seed Raised $3.5M · modeled $131.8M (est)Madrigal Pharmaceuticals, Inc. · Seed Raised $3.4M · modeled $128.4M (est)Hydropothecary Corp · Seed Raised $3.3M · modeled $124.6M (est)SapVax, LLC · Seed Raised $3.3M · modeled $123.6M (est)VersaPeutics, Inc. · Seed Raised $3.8M · modeled $121.7M (est)Westwood Life Sciences, Llc · Seed Raised $3.1M · modeled $116.3M (est)Har-Kcy, Llc · Seed Raised $3.0M · modeled $114.3M (est)Havix Group, Inc (this company) Raised $3.0M · modeled $22.8M (est)Havix Group, Inc
CompanyStageRaised · realValue · estvs peer med.
Chase Therapeutics CorpSeed$5.3M$152.2M2.52×
Acura Pharmaceuticals, IncSeed$4.0M$152.2M2.52×
Paragon Biosciences Skyline Capital, LLCSeed$4.0M$150.9M2.50×
Phoenix PharmaLabs IncSeed$3.5M$133.1M2.21×
Saghmos Therapeutics, Inc.Seed$3.5M$133.1M2.21×
Immucell Corp /De/Seed$3.5M$131.8M2.19×
Madrigal Pharmaceuticals, Inc.Seed$3.4M$128.4M2.13×
Hydropothecary CorpSeed$3.3M$124.6M2.07×
SapVax, LLCSeed$3.3M$123.6M2.05×
VersaPeutics, Inc.Seed$3.8M$121.7M2.02×
Westwood Life Sciences, LlcSeed$3.1M$116.3M1.93×
Har-Kcy, LlcSeed$3.0M$114.3M1.90×
Havix Group, Inc this companySeed$3.0M$22.8M0.38×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.9M2015-08-10$9.4M$71.3M85%
Seed$500K2017-02-01$2.5M$19.0M90%
Seed$600K2017-10-20$3.0M$22.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.9M2015-08-10
    • First recorded raise — entered as Seed.
    • 3 investors on this round.
  2. Seed$500K2017-02-01
    • Raised 18 mo later, in step with the ~13 mo sector norm.
    • Round 3.8× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  3. Seed$600K2017-10-20
    • Raised 9 mo later, in step with the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 1 investor on this round.
Intelligence
2018 ~Q4
Modeled next raise · ~13mo cadence
$720K
Modeled next size est.range $600K$1.2M
1.2×
Last step-up
$1.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Swapnil Shah2 other2017-10
Ravi Patel1 other2017-10
Ameet Vyas2017-02
Ashok Barot2017-02
Ashokkumar V Barot2015-08
Dhananjay A Barot2015-08
Dhananjay Barot2017-02
Gaurang Desai2017-02
Pankaj Chaudhari2017-02
Registry & provenance

Havix Group, Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1650186
SEC CIK
2015
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Adtech Pharma, Inc.PharmaceuticalsSeed$3.0M$17.0Msame sector · same stage
Myosin Therapeutics Inc.PharmaceuticalsSeed$3.0M$32.4Msame sector · same stage
Shape Pharmaceuticals, Inc.PharmaceuticalsSeed$3.0M$38.0Msame sector · same stage
Scinai Immunotherapeutics Ltd.PharmaceuticalsSeed$3.0M$10.5Msame sector · same stage
AION Healthspan, Inc.PharmaceuticalsSeed$2.9M$28.5Msame sector · same stage
Supreme Pharmaceuticals Inc.PharmaceuticalsSeed$2.9M$14.1Msame sector · same stage
TrippBio, Inc.PharmaceuticalsSeed$2.9M$10.8Msame sector · same stage
Earth Science Tech, Inc.PharmaceuticalsSeed$2.8M$7.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Navitor Pharmaceuticals, Inc.PharmaceuticalsSeries B$686.4M86%
MedAvail Holdings, Inc.PharmaceuticalsSeries B$679.3M85%
MBX Biosciences, Inc.PharmaceuticalsSeries C$724.1M84%
VasoRx, Inc.PharmaceuticalsSeed$117.9M84%
Hapten Sciences, Inc.PharmaceuticalsSeed$64.2M84%
Vaccinex, Inc.PharmaceuticalsSeries A$936K84%
Vapogenix, Inc.PharmaceuticalsSeries A$50.6M84%
Soligenix, Inc.PharmaceuticalsSeries A$60.8M84%
Frequently asked
How much funding has Havix Group, Inc raised?
Havix Group, Inc has raised approximately $3.0M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Havix Group, Inc's estimated valuation?
Provath's modeled valuation for Havix Group, Inc is approximately $22.8M (modeled range $454K–$179.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Havix Group, Inc at?
Havix Group, Inc's latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Oct 20.
What does Havix Group, Inc do and where is it based?
Havix Group, Inc operates in the Pharmaceuticals sector, based in HOSCHTON.
Explore related

See where Havix Group, Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Havix Group, Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.